Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021)

Avalo Therapeutics' Liabilities from Discontinued Operations history spans 4 years, with the latest figure at 10000.0 for Q3 2021.

  • For Q3 2021, Liabilities from Discontinued Operations fell 99.83% year-over-year to 10000.0; the TTM value through Sep 2021 reached 10000.0, down 99.83%, while the annual FY2020 figure was 1341000.0, 23.59% down from the prior year.
  • Liabilities from Discontinued Operations reached 10000.0 in Q3 2021 per AVTX's latest filing, down from 98000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 7549631.0 in Q4 2018 to a low of 10000.0 in Q3 2021.
  • Average Liabilities from Discontinued Operations over 4 years is 3195086.56, with a median of 1755000.0 recorded in 2019.
  • Peak YoY movement for Liabilities from Discontinued Operations: fell 23.59% in 2020, then tumbled 99.83% in 2021.
  • A 4-year view of Liabilities from Discontinued Operations shows it stood at 7549631.0 in 2018, then plummeted by 76.75% to 1755000.0 in 2019, then decreased by 23.59% to 1341000.0 in 2020, then plummeted by 99.25% to 10000.0 in 2021.
  • Per Business Quant, the three most recent readings for AVTX's Liabilities from Discontinued Operations are 10000.0 (Q3 2021), 98000.0 (Q2 2021), and 209000.0 (Q1 2021).